Alaskan Malamute Polyneuropathy (AMPN) is an inherited neurological disorder that affects the peripheral nerves—the network responsible for transmitting signals between the brain, spinal cord, and muscles. When these nerves fail to function properly, affected dogs experience progressive weakness, loss of coordination, and difficulty performing normal movements. AMPN is considered a serious but manageable condition when identified early, and responsible breeding practices have significantly reduced its prevalence in recent years.
AMPN is caused by a mutation in the NDRG1 gene, which plays a vital role in maintaining healthy nerve cells. The condition follows an autosomal recessive inheritance pattern, meaning a dog must inherit two copies of the mutated gene—one from each parent—to develop the disease. Dogs with only one copy are carriers: they show no symptoms but can pass the mutation to their offspring. Because carriers appear outwardly healthy, DNA testing is essential for preventing the condition from being unknowingly bred into future generations.
Clinical signs of AMPN typically appear between 3 and 19 months of age, although the exact onset can vary. Early symptoms often include subtle changes such as reduced stamina, an unusual gait, or difficulty jumping or climbing stairs. As the disease progresses, affected dogs may develop hind‑limb weakness, muscle atrophy, and a characteristic “bunny‑hopping” movement. Some dogs also show decreased reflexes or struggle to maintain balance. Despite these mobility challenges, AMPN does not cause pain, and many dogs remain bright, alert, and eager to interact with their families.
Diagnosis usually involves a combination of clinical examination, neurological assessment, and genetic testing. While nerve conduction studies or biopsies can provide additional information, the NDRG1 DNA test is the most reliable and accessible method for confirming whether a dog is clear, a carrier, or affected. This makes it an invaluable tool for breeders committed to maintaining the long‑term health of the Alaskan Malamute breed.
There is currently no cure for AMPN, but supportive care can help affected dogs enjoy a good quality of life. Management strategies may include controlled exercise, physiotherapy, and environmental adjustments to reduce the risk of falls. Because the condition is non‑painful and progresses slowly, many dogs adapt well with the right support. However, they should not be used for breeding, as they will always pass the mutated gene to their offspring.
From a breed‑health perspective, the most effective way to prevent AMPN is through responsible genetic screening. By ensuring that at least one parent in any mating is clear of the mutation, breeders can avoid producing affected puppies while still maintaining genetic diversity within the breed. This balanced approach protects the health of future generations without unnecessarily excluding carriers from breeding programmes.
AMPN serves as a powerful example of how modern DNA testing empowers breeders, owners, and breed clubs to work together in safeguarding the wellbeing of the Alaskan Malamute. Through awareness, education, and thoughtful breeding decisions, the condition can be effectively controlled, ensuring that these iconic Arctic dogs continue to thrive for generations to come.
